Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

LOXO-305 Comes Out Swinging In Battle Of BTK Inhibitors

Lilly's Loxo Presents Positive Phase I/II Data In MCL At ASH

Executive Summary

Pathway open for drug as post-covalent BTK option as Loxo gears up for "risky" Phase III head-to-head study in Q1 2021.

You may also be interested in...



CAR-Ts May Be Closer Competitors To Lilly’s Jaypirca Than Fellow BTK Inhibitors

The Loxo@Lilly drug got FDA accelerated approval in mantle cell lymphoma as the first non-covalent BTK inhibitor, enabling its use in post-BTKi disease.

Keeping Track Of Rolling Submissions: Gamida Cell, Roche, Lilly And Reata Are Latest To Use Fast Track

Applications are underway for omidubicel, mosenutuzumab, pirtobrutinib and omaveloxolone.

After Lybalvi’s Solid Early Launch, Alkermes Touts Neuropsychiatry Potential

Alkermes tells J.P. Morgan audience it hopes new combo Lybalvi and established Aristada will boost each other and the neuropsychiatric franchise. But the firm noted its addiction drug Vivitrol requires complicated commercial plan.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC143430

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel